These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24885272)

  • 1. Deciphering the mechanism behind Fibroblast Growth Factor (FGF) induced biphasic signal-response profiles.
    Kanodia J; Chai D; Vollmer J; Kim J; Raue A; Finn G; Schoeberl B
    Cell Commun Signal; 2014 May; 12():34. PubMed ID: 24885272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative assessment of FGF regulation by cell surface heparan sulfates.
    Berry D; Shriver Z; Venkataraman G; Sasisekharan R
    Biochem Biophys Res Commun; 2004 Feb; 314(4):994-1000. PubMed ID: 14751231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast Growth Factor 2 Protein Stability Provides Decreased Dependence on Heparin for Induction of FGFR Signaling and Alters ERK Signaling Dynamics.
    Koledova Z; Sumbal J; Rabata A; de La Bourdonnaye G; Chaloupkova R; Hrdlickova B; Damborsky J; Stepankova V
    Front Cell Dev Biol; 2019; 7():331. PubMed ID: 31921844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic insight into activation of MAPK signaling by pro-angiogenic factors.
    Song M; Finley SD
    BMC Syst Biol; 2018 Dec; 12(1):145. PubMed ID: 30591051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2.
    Chua CC; Rahimi N; Forsten-Williams K; Nugent MA
    Circ Res; 2004 Feb; 94(3):316-23. PubMed ID: 14684627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERK and Akt exhibit distinct signaling responses following stimulation by pro-angiogenic factors.
    Song M; Finley SD
    Cell Commun Signal; 2020 Jul; 18(1):114. PubMed ID: 32680529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing fibroblast growth factor dimerization and role of heparin-like glycosaminoglycans in modulating dimerization and signaling.
    Kwan CP; Venkataraman G; Shriver Z; Raman R; Liu D; Qi Y; Varticovski L; Sasisekharan R
    J Biol Chem; 2001 Jun; 276(26):23421-9. PubMed ID: 11292822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural specificity of heparin binding in the fibroblast growth factor family of proteins.
    Raman R; Venkataraman G; Ernst S; Sasisekharan V; Sasisekharan R
    Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2357-62. PubMed ID: 12604799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway.
    Sulpice E; Bryckaert M; Lacour J; Contreres JO; Tobelem G
    Blood; 2002 Nov; 100(9):3087-94. PubMed ID: 12384403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of heparin mimetics on assembly of the FGF.FGFR4 signaling complex.
    Saxena K; Schieborr U; Anderka O; Duchardt-Ferner E; Elshorst B; Gande SL; Janzon J; Kudlinzki D; Sreeramulu S; Dreyer MK; Wendt KU; Herbert C; Duchaussoy P; Bianciotto M; Driguez PA; Lassalle G; Savi P; Mohammadi M; Bono F; Schwalbe H
    J Biol Chem; 2010 Aug; 285(34):26628-40. PubMed ID: 20547770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparan sulphate glycosaminoglycans derived from endothelial cells and smooth muscle cells differentially modulate fibroblast growth factor-2 biological activity through fibroblast growth factor receptor-1.
    Berry D; Shriver Z; Natke B; Kwan CP; Venkataraman G; Sasisekharan R
    Biochem J; 2003 Jul; 373(Pt 1):241-9. PubMed ID: 12659634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells.
    Marek L; Ware KE; Fritzsche A; Hercule P; Helton WR; Smith JE; McDermott LA; Coldren CD; Nemenoff RA; Merrick DT; Helfrich BA; Bunn PA; Heasley LE
    Mol Pharmacol; 2009 Jan; 75(1):196-207. PubMed ID: 18849352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand concentration is a driver of divergent signaling and pleiotropic cellular responses to FGF.
    Garcia-Maya M; Anderson AA; Kendal CE; Kenny AV; Edwards-Ingram LC; Holladay A; Saffell JL
    J Cell Physiol; 2006 Feb; 206(2):386-93. PubMed ID: 16155940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins.
    Krejci P; Masri B; Salazar L; Farrington-Rock C; Prats H; Thompson LM; Wilcox WR
    J Biol Chem; 2007 Feb; 282(5):2929-36. PubMed ID: 17145761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF signaling network in the gastrointestinal tract (review).
    Katoh M; Katoh M
    Int J Oncol; 2006 Jul; 29(1):163-8. PubMed ID: 16773196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor receptor signaling activates the human interstitial collagenase promoter via the bipartite Ets-AP1 element.
    Newberry EP; Willis D; Latifi T; Boudreaux JM; Towler DA
    Mol Endocrinol; 1997 Jul; 11(8):1129-44. PubMed ID: 9212060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly.
    Ibrahimi OA; Zhang F; Hrstka SC; Mohammadi M; Linhardt RJ
    Biochemistry; 2004 Apr; 43(16):4724-30. PubMed ID: 15096041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.
    Li Q; Alsaidan OA; Ma Y; Kim S; Liu J; Albers T; Liu K; Beharry Z; Zhao S; Wang F; Lebedyeva I; Cai H
    J Biol Chem; 2018 Apr; 293(17):6434-6448. PubMed ID: 29540482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
    Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
    Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The kinetics of FGF-2 binding to heparan sulfate proteoglycans and MAP kinase signaling.
    Forsten-Williams K; Chua CC; Nugent MA
    J Theor Biol; 2005 Apr; 233(4):483-99. PubMed ID: 15748910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.